OraSure Technologies (NASDAQ:OSUR) Lowered to “Hold” Rating by StockNews.com

StockNews.com lowered shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research note published on Thursday morning.

OraSure Technologies Trading Down 2.4 %

Shares of NASDAQ OSUR opened at $3.62 on Thursday. The stock’s 50-day moving average is $3.86 and its 200 day moving average is $4.11. The stock has a market cap of $270.03 million, a price-to-earnings ratio of 24.13 and a beta of 0.05. OraSure Technologies has a 1-year low of $3.52 and a 1-year high of $8.33.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm had revenue of $39.92 million for the quarter, compared to the consensus estimate of $38.97 million. During the same period last year, the firm posted $0.27 earnings per share. The business’s revenue was down 55.2% compared to the same quarter last year. On average, analysts forecast that OraSure Technologies will post -0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Atom Investors LP purchased a new stake in OraSure Technologies during the 3rd quarter valued at about $49,000. Creative Planning bought a new position in shares of OraSure Technologies in the third quarter worth approximately $54,000. Mackenzie Financial Corp purchased a new position in shares of OraSure Technologies in the second quarter worth $72,000. Intech Investment Management LLC bought a new stake in OraSure Technologies during the 3rd quarter valued at $84,000. Finally, SkyView Investment Advisors LLC boosted its position in OraSure Technologies by 100.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 12,000 shares during the period. Hedge funds and other institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.